Archer Materials（38A）株式概要アーチャーマテリアルズ社は、量子コンピューターや医療診断に関連する半導体デバイスやセンサーの開発・商業化をオーストラリアで行っているテクノロジー企業である。 詳細38A ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性6/6配当金0/6報酬過去5年間の収益は年間0.6%増加しました。 リスク分析意味のある時価総額がありません ( €49M )German市場と比較した過去 3 か月間の株価の変動意味のある収益がありません ( A$2M )すべてのリスクチェックを見る38A Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€0.1865.8% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-14m8m2016201920222025202620282031Revenue AU$8.1mEarnings AU$1.3mAdvancedSet Fair ValueView all narrativesArcher Materials Limited 競合他社PlanoptikSymbol: XTRA:P4OMarket cap: €44.6mFirst SensorSymbol: XTRA:SISMarket cap: €553.1mELES Semiconductor EquipmentSymbol: DB:1EPMarket cap: €56.2mElmos SemiconductorSymbol: XTRA:ELGMarket cap: €3.2b価格と性能株価の高値、安値、推移の概要Archer Materials過去の株価現在の株価AU$0.1852週高値AU$0.2952週安値AU$0.11ベータ-0.241ヶ月の変化1.33%3ヶ月変化-17.84%1年変化23.24%3年間の変化-11.46%5年間の変化-63.15%IPOからの変化125.19%最新ニュースBoard Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Director Bernadette Harkin was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Sep 19Archer Materials Limited, Annual General Meeting, Nov 20, 2025Archer Materials Limited, Annual General Meeting, Nov 20, 2025.お知らせ • May 05+ 1 more updateArcher Materials Limited Announces Resignation of Damien Connor, Chief Financial Officer, Effective 30 June 2025Archer Materials Limited announced Mr. Damien Connor, the Company's Chief Financial Officer has provided notice of resignation to the Company. Mr. Connor has agreed to assist as required to ensure a smooth transition through to 30 June 2025.Board Change • Dec 30Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 1 highly experienced director. Independent Non-Executive Director Bernadette Harkin was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Nov 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 1 highly experienced director. Independent Non-Executive Director Bernadette Harkin was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Oct 18Archer Materials Limited, Annual General Meeting, Nov 20, 2024Archer Materials Limited, Annual General Meeting, Nov 20, 2024. Location: stone & chalk sydney scaleup hub, level 2, 477 pitt street, haymarket, 2000., Australia最新情報をもっと見るRecent updatesBoard Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Director Bernadette Harkin was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Sep 19Archer Materials Limited, Annual General Meeting, Nov 20, 2025Archer Materials Limited, Annual General Meeting, Nov 20, 2025.お知らせ • May 05+ 1 more updateArcher Materials Limited Announces Resignation of Damien Connor, Chief Financial Officer, Effective 30 June 2025Archer Materials Limited announced Mr. Damien Connor, the Company's Chief Financial Officer has provided notice of resignation to the Company. Mr. Connor has agreed to assist as required to ensure a smooth transition through to 30 June 2025.Board Change • Dec 30Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 1 highly experienced director. Independent Non-Executive Director Bernadette Harkin was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Nov 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 1 highly experienced director. Independent Non-Executive Director Bernadette Harkin was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Oct 18Archer Materials Limited, Annual General Meeting, Nov 20, 2024Archer Materials Limited, Annual General Meeting, Nov 20, 2024. Location: stone & chalk sydney scaleup hub, level 2, 477 pitt street, haymarket, 2000., Australiaお知らせ • Jul 13Mohammad Choucair to Step Down as Chief Executive Officer of Archer Materials Limited in January 2025Archer Materials Limited announced the departure of Dr. Mohammad Choucair as Chief Executive Officer ("CEO"). Mohammad will step down from the CEO role in January 2025 to ensure a smooth transition and handover. Mohammad retires from the Company for personal reasons.お知らせ • Mar 15Archer Materials Limited Designs Miniaturised Version of Biochip Biochip Graphene Field Effect Transistor ChipArcher Materials Limited has designed a miniaturised version of its Biochip graphene field effect transistor (“gFET”) chip for fabrication at a commercial foundry. The Archer Biochip contains a sensing region of which the gFET is the core component. Each gFET chip contains multiple gFETs, each of which is a transistor, which acts as a sensor. Archer has miniaturised the total chip size by redesigning the layout of the circuits creating these gFET transistors. The new miniaturised design has been sent to a foundry partner for a whole-wafer fabrication of reduced size gFET chips, which Archer intends to integrate with other parts of the Biochip technology. The new gFET chip design has been significantly reduced in size over earlier designs of 10mm x 10mm to 1.5mm x 1.5mm. It will be tested on a four-inch wafer which is expected to produce 1375 chips on it, compared to the 45 chips produced using earlier designs in previous four-inch wafer fabrication runs. The chip will be fabricated by Applied Nanolayers (“ANL”), based in the Netherlands, which has fabricated earlier designs of Archer’s gFETs (ASX ann. 14 September 2023). Independent to wafer runs at ANL, Archer has also sent gFET designs to a foundry in Spain for fabrication, with delivery anticipated within the first half of 2024 (ASX ann. 11 December 2023). Archer applies the ‘fabless’ chipmaker model by designing, researching, and developing its chips, while outsourcing manufacturing to specialised companies in the semiconductor supply chain. This includes the creation of a new miniaturised Biochip gFET chip design, sending the design for a whole wafer run in a commercial foundry, and deciding on the chip assembly and semiconductor device electronics packaging and related electrical testing. The wafer will be diced and assembled at Archer’s newly established outsourced semiconductor assembly and testing (“OSAT”) partner, AOI Electronics in Japan. The OSAT includes moulding, dicing, and lead frame design for this dedicated wafer assembly, and also device electronic shorting and related packaging testing. These new capabilities are key in advancing the Biochip development to interfacing and integration with miniaturised gFET chip sensor designs. Delivery of the packaged chips is anticipated in mid-2024.お知らせ • Nov 02Archer Materials Limited Demonstrates Multiplexing Readout for its Advanced Biochip Graphene Field Effect Transistor DeviceArcher Materials Limited has demonstrated multiplexing readout for its advanced Biochip graphene field effect transistor (gFET) device. Archer confirmed single-device multiplexing using four advanced gFETs as sensors, which were integrated into the Archer advanced Biochip platform that was announced on 14 September 2023. This is significant as Archer intends to apply its multiplexing capability in the Biochip to test for multiple diseases on a single chip at once. Archer designed and developed the new hardware and software systems to readout the signal from the four advanced gFET sensors at once on a single chip. This is a significant advance over the earlier generation of the Biochip system, which could only activate one-sensor-at-a-time. The new Biochip system with multiplexing capability also provides automated hands-free operation, as it integrates liquid handling automation and data acquisition. The software developed by Archer can display all single and time series measurements in real-time for the four gFET sensors simultaneously.お知らせ • Oct 28Archer Materials Limited, Annual General Meeting, Nov 29, 2023Archer Materials Limited, Annual General Meeting, Nov 29, 2023, at 10:30 E. Australia Standard Time. Location: KPMG, Level 38, Tower Three, International Towers Sydney 300 Barangaroo Avenue Sydney New South Wales Australia Agenda: To consider he Remuneration Report for the year ended 30 June 2023; to consider Re-election of Bernadette Harkin as a Director; to consider Approval of Issues of Securities under the New Performance Rights Plan and Share Option Plan; to consider Modification of the Company's Constitution; to consider Approval of 10% additional placement capacity; to consider Renewal of proportional takeover provisions in the Constitution; and to consider other matters.New Risk • Aug 17New major risk - Revenue sizeThe company makes less than US$1m in revenue. Total revenue: AU$1.6m (US$997k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 53% per year over the past 5 years. Revenue is less than US$1m (AU$1.6m revenue, or US$997k). Minor Risks Shareholders have been diluted in the past year (2.6% increase in shares outstanding). Market cap is less than US$100m (€76.7m market cap, or US$83.4m).お知らせ • Aug 01Archer Materials Limited Further Enhances Biochip gFET Design for Advanced Sensing and Send to Commercial Foundry PartnerArcher Materials Limited has developed a next generation biochip fabrication to better detect and control disease samples on a single graphene field effect transistor ("gFET") design. The gFET design also has functional surfaces and components, for both the sensor and control of the biochip platform. There is also an integration of gFET design components that allow for the real-time fine tuning and control of the electronic properties of the graphene. This has the potential advantage of biosensors that are re-usable, leading to an extended device lifetime. In addition, Archer has improved its biochip system platform testing capabilities to develop a more accurate sensor. The upgraded automated testing platform conducts both control software and readout hardware with improved efficiency. The software is also progressing towards automated data analysis, so end users can extract high quality data. This new more complex gFET design complements the proof-of-concept biosensing gFET announced on 13 July 2023. The earlier design was submitted to a commercial foundry for a Multi-Project Wafer run, with the completed devices expected to be delivered by the end of 2023. The new advanced device designs which are the subject of this announcement have now been submitted to a foundry in the Netherlands for a whole wafer run (the previous 'simpler' design was submitted to a foundry in Germany for a Multi- Project Wafer ("MPW") run). An MPW is where Archer's device design is imprinted on a small area of a wafer with the designs of other companies on the same wafer. The new more complex gFet design will be fabricated all over one, stand-alone four-inch wafer. The new advanced gFET device design and whole wafer run in a commercial foundry is an example of how Archer is now moving towards a streamlined commercialization model that closely aligns to the 'fabless' model (i.e. Archer focuses on designing and developing its chips and outsources the manufacturing to specialized foundries). The new gFET device designs and related processes form the basis of intellectual property that is 100% owned by Archer.お知らせ • Jul 14Archer Materials Limited Transfers Biochip Graphene Sensor Technology Design to A Commercial Fab to Verify ScalabilityArcher Materials Limited has completed a proof of concept biosensing graphene transistor for use in its biochip, and submitted the technology design to a commercial foundry to verify scalability. The Archer-designed gFET sensing chips will be produced by a commercial foundry, with the aim of Archer validating its design to ensure appropriate scalability for the manufacturing process. Archer expects completed runs to arrive at the end of 2023. The runs will be evaluated to test which foundry and process are best suited to Archer's technology. Archer's design and process can then be scaled to manufacture complete wafers containing the graphene-based sensors for biochip integration in collaboration with a range of different commercial foundries. Archer has, in parallel, started discussions with potential global foundry partners for initial small production runs of its graphene chip designs to evaluate the reliability of the product. The latest development follows the recent announcement on 10 March 2023 in which the Company gained electronic control of the sensitivity of its incorporated gFET devices so it can better target biomolecules. This followed Archer's early-stage biochip prototype with an integrated system platform for biosensing announced to the market on 16 November 2022, after having developed a 'wettable' gFET announced on 24 October 2022.Executive Departure • Nov 24Independent Non-Executive Director Alice McCleary has left the companyOn the 24th of November, Alice McCleary's tenure as Independent Non-Executive Director ended after 14.8 years in the role. As of September 2021, Alice still personally held 3.87m shares (€4.1m worth at the time). Alice is the only executive to leave the company over the last 12 months.Reported Earnings • Sep 23Full year 2021 earnings released: AU$0.009 loss per share (vs AU$0.014 loss in FY 2020)Full year 2021 results: Net loss: AU$3.33m (loss widened 19% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has increased by 196% per year, which means it is well ahead of earnings.Reported Earnings • Feb 26First half 2021 earnings released: AU$0.028 loss per share (vs AU$0.009 loss in 1H 2020)First half 2021 results: Net loss: AU$6.41m (loss widened 261% from 1H 2020). Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has increased by 123% per year, which means it is well ahead of earnings.Is New 90 Day High Low • Feb 23New 90-day high: €0.80The company is up 142% from its price of €0.33 on 25 November 2020. The German market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Metals and Mining industry, which is up 56% over the same period.Is New 90 Day High Low • Jan 14New 90-day high: €0.37The company is up 25% from its price of €0.30 on 16 October 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Metals and Mining industry, which is up 60% over the same period.Is New 90 Day High Low • Dec 30New 90-day high: €0.36The company is up 18% from its price of €0.30 on 01 October 2020. The German market is up 9.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Metals and Mining industry, which is up 46% over the same period.Reported Earnings • Sep 27Full year earnings released - €0.014 loss per shareOver the last 12 months the company has reported total losses of AU$2.80m, with losses widening by 61% from the prior year.株主還元38ADE SemiconductorDE 市場7D-13.6%11.3%3.2%1Y23.2%128.0%2.5%株主還元を見る業界別リターン: 38A過去 1 年間で128 % の収益を上げたGerman Semiconductor業界を下回りました。リターン対市場: 38A過去 1 年間で2.5 % の収益を上げたGerman市場を上回りました。価格変動Is 38A's price volatile compared to industry and market?38A volatility38A Average Weekly Movement10.5%Semiconductor Industry Average Movement9.2%Market Average Movement6.1%10% most volatile stocks in DE Market13.3%10% least volatile stocks in DE Market2.7%安定した株価: 38Aの株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 38Aの weekly volatility ( 11% ) は過去 1 年間安定していますが、依然としてGermanの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2007n/aSimon Ruffellarcherx.com.auアーチャーマテリアルズ社は、量子コンピューターや医療診断に関連する半導体デバイスやセンサーの開発・商業化をオーストラリアで行っているテクノロジー企業である。主に、室温で動作し現代の電子機器に統合可能な量子ビット・プロセッサー・チップや、グラフェンベースのラボオンチップ・バイオチップ技術の開発に注力している。同社は以前はArcher Exploration Limitedとして知られていたが、2019年10月にArcher Materials Limitedに社名を変更した。アーチャー・マテリアルズ・リミテッドは2007年に法人化され、オーストラリアのアデレードを拠点としている。もっと見るArcher Materials Limited 基礎のまとめArcher Materials の収益と売上を時価総額と比較するとどうか。38A 基礎統計学時価総額€48.55m収益（TTM）-€3.41m売上高(TTM)€1.37m35.6xP/Sレシオ-14.2xPER（株価収益率38A は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計38A 損益計算書（TTM）収益AU$2.22m売上原価AU$0売上総利益AU$2.22mその他の費用AU$7.77m収益-AU$5.55m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.022グロス・マージン100.00%純利益率-249.73%有利子負債／自己資本比率0%38A の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 04:35終値2026/05/22 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Archer Materials Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Director Bernadette Harkin was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Sep 19Archer Materials Limited, Annual General Meeting, Nov 20, 2025Archer Materials Limited, Annual General Meeting, Nov 20, 2025.
お知らせ • May 05+ 1 more updateArcher Materials Limited Announces Resignation of Damien Connor, Chief Financial Officer, Effective 30 June 2025Archer Materials Limited announced Mr. Damien Connor, the Company's Chief Financial Officer has provided notice of resignation to the Company. Mr. Connor has agreed to assist as required to ensure a smooth transition through to 30 June 2025.
Board Change • Dec 30Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 1 highly experienced director. Independent Non-Executive Director Bernadette Harkin was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Nov 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 1 highly experienced director. Independent Non-Executive Director Bernadette Harkin was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 18Archer Materials Limited, Annual General Meeting, Nov 20, 2024Archer Materials Limited, Annual General Meeting, Nov 20, 2024. Location: stone & chalk sydney scaleup hub, level 2, 477 pitt street, haymarket, 2000., Australia
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Director Bernadette Harkin was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Sep 19Archer Materials Limited, Annual General Meeting, Nov 20, 2025Archer Materials Limited, Annual General Meeting, Nov 20, 2025.
お知らせ • May 05+ 1 more updateArcher Materials Limited Announces Resignation of Damien Connor, Chief Financial Officer, Effective 30 June 2025Archer Materials Limited announced Mr. Damien Connor, the Company's Chief Financial Officer has provided notice of resignation to the Company. Mr. Connor has agreed to assist as required to ensure a smooth transition through to 30 June 2025.
Board Change • Dec 30Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 1 highly experienced director. Independent Non-Executive Director Bernadette Harkin was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Nov 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 1 highly experienced director. Independent Non-Executive Director Bernadette Harkin was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 18Archer Materials Limited, Annual General Meeting, Nov 20, 2024Archer Materials Limited, Annual General Meeting, Nov 20, 2024. Location: stone & chalk sydney scaleup hub, level 2, 477 pitt street, haymarket, 2000., Australia
お知らせ • Jul 13Mohammad Choucair to Step Down as Chief Executive Officer of Archer Materials Limited in January 2025Archer Materials Limited announced the departure of Dr. Mohammad Choucair as Chief Executive Officer ("CEO"). Mohammad will step down from the CEO role in January 2025 to ensure a smooth transition and handover. Mohammad retires from the Company for personal reasons.
お知らせ • Mar 15Archer Materials Limited Designs Miniaturised Version of Biochip Biochip Graphene Field Effect Transistor ChipArcher Materials Limited has designed a miniaturised version of its Biochip graphene field effect transistor (“gFET”) chip for fabrication at a commercial foundry. The Archer Biochip contains a sensing region of which the gFET is the core component. Each gFET chip contains multiple gFETs, each of which is a transistor, which acts as a sensor. Archer has miniaturised the total chip size by redesigning the layout of the circuits creating these gFET transistors. The new miniaturised design has been sent to a foundry partner for a whole-wafer fabrication of reduced size gFET chips, which Archer intends to integrate with other parts of the Biochip technology. The new gFET chip design has been significantly reduced in size over earlier designs of 10mm x 10mm to 1.5mm x 1.5mm. It will be tested on a four-inch wafer which is expected to produce 1375 chips on it, compared to the 45 chips produced using earlier designs in previous four-inch wafer fabrication runs. The chip will be fabricated by Applied Nanolayers (“ANL”), based in the Netherlands, which has fabricated earlier designs of Archer’s gFETs (ASX ann. 14 September 2023). Independent to wafer runs at ANL, Archer has also sent gFET designs to a foundry in Spain for fabrication, with delivery anticipated within the first half of 2024 (ASX ann. 11 December 2023). Archer applies the ‘fabless’ chipmaker model by designing, researching, and developing its chips, while outsourcing manufacturing to specialised companies in the semiconductor supply chain. This includes the creation of a new miniaturised Biochip gFET chip design, sending the design for a whole wafer run in a commercial foundry, and deciding on the chip assembly and semiconductor device electronics packaging and related electrical testing. The wafer will be diced and assembled at Archer’s newly established outsourced semiconductor assembly and testing (“OSAT”) partner, AOI Electronics in Japan. The OSAT includes moulding, dicing, and lead frame design for this dedicated wafer assembly, and also device electronic shorting and related packaging testing. These new capabilities are key in advancing the Biochip development to interfacing and integration with miniaturised gFET chip sensor designs. Delivery of the packaged chips is anticipated in mid-2024.
お知らせ • Nov 02Archer Materials Limited Demonstrates Multiplexing Readout for its Advanced Biochip Graphene Field Effect Transistor DeviceArcher Materials Limited has demonstrated multiplexing readout for its advanced Biochip graphene field effect transistor (gFET) device. Archer confirmed single-device multiplexing using four advanced gFETs as sensors, which were integrated into the Archer advanced Biochip platform that was announced on 14 September 2023. This is significant as Archer intends to apply its multiplexing capability in the Biochip to test for multiple diseases on a single chip at once. Archer designed and developed the new hardware and software systems to readout the signal from the four advanced gFET sensors at once on a single chip. This is a significant advance over the earlier generation of the Biochip system, which could only activate one-sensor-at-a-time. The new Biochip system with multiplexing capability also provides automated hands-free operation, as it integrates liquid handling automation and data acquisition. The software developed by Archer can display all single and time series measurements in real-time for the four gFET sensors simultaneously.
お知らせ • Oct 28Archer Materials Limited, Annual General Meeting, Nov 29, 2023Archer Materials Limited, Annual General Meeting, Nov 29, 2023, at 10:30 E. Australia Standard Time. Location: KPMG, Level 38, Tower Three, International Towers Sydney 300 Barangaroo Avenue Sydney New South Wales Australia Agenda: To consider he Remuneration Report for the year ended 30 June 2023; to consider Re-election of Bernadette Harkin as a Director; to consider Approval of Issues of Securities under the New Performance Rights Plan and Share Option Plan; to consider Modification of the Company's Constitution; to consider Approval of 10% additional placement capacity; to consider Renewal of proportional takeover provisions in the Constitution; and to consider other matters.
New Risk • Aug 17New major risk - Revenue sizeThe company makes less than US$1m in revenue. Total revenue: AU$1.6m (US$997k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 53% per year over the past 5 years. Revenue is less than US$1m (AU$1.6m revenue, or US$997k). Minor Risks Shareholders have been diluted in the past year (2.6% increase in shares outstanding). Market cap is less than US$100m (€76.7m market cap, or US$83.4m).
お知らせ • Aug 01Archer Materials Limited Further Enhances Biochip gFET Design for Advanced Sensing and Send to Commercial Foundry PartnerArcher Materials Limited has developed a next generation biochip fabrication to better detect and control disease samples on a single graphene field effect transistor ("gFET") design. The gFET design also has functional surfaces and components, for both the sensor and control of the biochip platform. There is also an integration of gFET design components that allow for the real-time fine tuning and control of the electronic properties of the graphene. This has the potential advantage of biosensors that are re-usable, leading to an extended device lifetime. In addition, Archer has improved its biochip system platform testing capabilities to develop a more accurate sensor. The upgraded automated testing platform conducts both control software and readout hardware with improved efficiency. The software is also progressing towards automated data analysis, so end users can extract high quality data. This new more complex gFET design complements the proof-of-concept biosensing gFET announced on 13 July 2023. The earlier design was submitted to a commercial foundry for a Multi-Project Wafer run, with the completed devices expected to be delivered by the end of 2023. The new advanced device designs which are the subject of this announcement have now been submitted to a foundry in the Netherlands for a whole wafer run (the previous 'simpler' design was submitted to a foundry in Germany for a Multi- Project Wafer ("MPW") run). An MPW is where Archer's device design is imprinted on a small area of a wafer with the designs of other companies on the same wafer. The new more complex gFet design will be fabricated all over one, stand-alone four-inch wafer. The new advanced gFET device design and whole wafer run in a commercial foundry is an example of how Archer is now moving towards a streamlined commercialization model that closely aligns to the 'fabless' model (i.e. Archer focuses on designing and developing its chips and outsources the manufacturing to specialized foundries). The new gFET device designs and related processes form the basis of intellectual property that is 100% owned by Archer.
お知らせ • Jul 14Archer Materials Limited Transfers Biochip Graphene Sensor Technology Design to A Commercial Fab to Verify ScalabilityArcher Materials Limited has completed a proof of concept biosensing graphene transistor for use in its biochip, and submitted the technology design to a commercial foundry to verify scalability. The Archer-designed gFET sensing chips will be produced by a commercial foundry, with the aim of Archer validating its design to ensure appropriate scalability for the manufacturing process. Archer expects completed runs to arrive at the end of 2023. The runs will be evaluated to test which foundry and process are best suited to Archer's technology. Archer's design and process can then be scaled to manufacture complete wafers containing the graphene-based sensors for biochip integration in collaboration with a range of different commercial foundries. Archer has, in parallel, started discussions with potential global foundry partners for initial small production runs of its graphene chip designs to evaluate the reliability of the product. The latest development follows the recent announcement on 10 March 2023 in which the Company gained electronic control of the sensitivity of its incorporated gFET devices so it can better target biomolecules. This followed Archer's early-stage biochip prototype with an integrated system platform for biosensing announced to the market on 16 November 2022, after having developed a 'wettable' gFET announced on 24 October 2022.
Executive Departure • Nov 24Independent Non-Executive Director Alice McCleary has left the companyOn the 24th of November, Alice McCleary's tenure as Independent Non-Executive Director ended after 14.8 years in the role. As of September 2021, Alice still personally held 3.87m shares (€4.1m worth at the time). Alice is the only executive to leave the company over the last 12 months.
Reported Earnings • Sep 23Full year 2021 earnings released: AU$0.009 loss per share (vs AU$0.014 loss in FY 2020)Full year 2021 results: Net loss: AU$3.33m (loss widened 19% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has increased by 196% per year, which means it is well ahead of earnings.
Reported Earnings • Feb 26First half 2021 earnings released: AU$0.028 loss per share (vs AU$0.009 loss in 1H 2020)First half 2021 results: Net loss: AU$6.41m (loss widened 261% from 1H 2020). Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has increased by 123% per year, which means it is well ahead of earnings.
Is New 90 Day High Low • Feb 23New 90-day high: €0.80The company is up 142% from its price of €0.33 on 25 November 2020. The German market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Metals and Mining industry, which is up 56% over the same period.
Is New 90 Day High Low • Jan 14New 90-day high: €0.37The company is up 25% from its price of €0.30 on 16 October 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Metals and Mining industry, which is up 60% over the same period.
Is New 90 Day High Low • Dec 30New 90-day high: €0.36The company is up 18% from its price of €0.30 on 01 October 2020. The German market is up 9.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Metals and Mining industry, which is up 46% over the same period.
Reported Earnings • Sep 27Full year earnings released - €0.014 loss per shareOver the last 12 months the company has reported total losses of AU$2.80m, with losses widening by 61% from the prior year.
